Skip to main content

Table 3 Transplant outcomes of the intervention group according to the number of feedback messages generated

From: ICT-based adherence monitoring in kidney transplant recipients: a randomized controlled trial

  Feedback ≥1 (n = 13) No feedback (n = 38) p value
Drug levels
 TAC trough level, ng/mL 5.1 ± 1.2 5.3 ± 1.1 0.574
 TAC CVa 29.4 ± 16.3 22.1 ± 12.0 0.155
 MPA trough level, μg/mL 2.4 ± 1.0 2.9 ± 1.8 0.332
 MPA CVa 36.6 ± 24.8 38.3 ± 14.3 0.754
eGFR
 4 weeks 71.5 ± 21.9 66.6 ± 16.9 0.474
 8 weeks 69.8 ± 22.7 67.3 ± 18.8 0.720
 12 weeks 66.4 ± 21.0 66.8 ± 19.1 0.946
 16 weeks 66.6 ± 19.4 67.9 ± 16.9 0.829
 20 weeks 66.9 ± 22.2 66.1 ± 16.6 0.914
 24 weeks 65.7 ± 23.5 65.0 ± 17.4 0.928
Number of events, n (%)
 De novo anti-HLA antibodies 1 (7.7) 2 (5.3) 0.748
 BK viremia 0 (0) 1 (2.6) 0.555
 BPAR  
 DCGL  
  1. Values are shown as mean ± standard deviation or number (%)
  2. BPAR Biopsy-proven acute rejection, CV Coefficient of variation, DCGL Death-censored graft loss, eGFR estimated glomerular filtration rate, HLA Human leukocyte antigen, MPA Mycophenolic acid, TAC Tacrolimus
  3. aCV = (standard deviation/mean) × 100%